Floatz logo

BUSULFANUM

Adult Acute Lymphoblastic Leukemia

Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranSmall moleculePhase 2/3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

65 Active assets in the Adult Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
METHOTREXATE
PETHEMA Foundation
Phase 4BBB
Cyclophosphamide
The First Affiliated Hospital of Zhengzhou University
Phase 4BBB
Dexasone
Shanxi Bethune Hospital
Phase 4BBB
CYTARABINE
PETHEMA Foundation
Phase 4BBB

View all 50 →

Same molecule, other indications

BUSULFANUM is also rated in:

myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
graft versus host diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →